Insulin Resistance – Drugs in Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Insulin Resistance – Drugs in Development, 2021, provides an overview of the Insulin Resistance (Metabolic Disorders) pipeline landscape.

Insulin resistance (IR) is a condition in which the body's cells become resistant to the effects of insulin. This occurs when insulin levels are sufficiently high over a prolonged period of time causing the body’s own sensitivity to the hormone to be reduced. Symptoms include lethargy, hunger, difficulty concentrating and high blood pressure. Predisposing factors include obesity and hypertension.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Insulin Resistance – Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Insulin Resistance (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Insulin Resistance (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Insulin Resistance and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 8 and 1 respectively.

Insulin Resistance (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Insulin Resistance (Metabolic Disorders).

– The pipeline guide reviews pipeline therapeutics for Insulin Resistance (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Insulin Resistance (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Insulin Resistance (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Insulin Resistance (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Insulin Resistance (Metabolic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Insulin Resistance (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Amolyt Pharma

Amryt Pharma Plc

CohBar Inc

Exscien Corp

Glycomantra Inc

Hanmi Pharmaceuticals Co Ltd

Lixte Biotechnology Holdings Inc

NorthSea Therapeutics BV

The Healthy Aging Co

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Insulin Resistance - Overview

Insulin Resistance - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Insulin Resistance - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Insulin Resistance - Companies Involved in Therapeutics Development

Amolyt Pharma

Amryt Pharma Plc

CohBar Inc

Exscien Corp

Glycomantra Inc

Hanmi Pharmaceuticals Co Ltd

Lixte Biotechnology Holdings Inc

NorthSea Therapeutics BV

The Healthy Aging Co

Insulin Resistance - Drug Profiles

ALF-5755 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZP-3404 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Target hOGG1 for Acute Lung Injury and Insulin Resistance - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-15136 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

icosabutate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LB-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

metreleptin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MOTS-c - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Immunology, Insulin Resistance and Musculoskeletal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TFD-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Insulin Resistance - Dormant Projects

Insulin Resistance - Product Development Milestones

Featured News & Press Releases

Mar 21, 2019: Alize Pharma3 to present data from its AZP-3404program in syndromes of severe insulin resistance at ENDO2019

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Insulin Resistance, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Insulin Resistance – Pipeline by Amolyt Pharma, 2021

Insulin Resistance – Pipeline by Amryt Pharma Plc, 2021

Insulin Resistance – Pipeline by CohBar Inc, 2021

Insulin Resistance – Pipeline by Exscien Corp, 2021

Insulin Resistance – Pipeline by Glycomantra Inc, 2021

Insulin Resistance – Pipeline by Hanmi Pharmaceuticals Co Ltd, 2021

Insulin Resistance – Pipeline by Lixte Biotechnology Holdings Inc, 2021

Insulin Resistance – Pipeline by NorthSea Therapeutics BV, 2021

Insulin Resistance – Pipeline by The Healthy Aging Co, 2021

Insulin Resistance – Dormant Projects, 2021

Insulin Resistance – Dormant Projects, 2021 (Contd..1)

Insulin Resistance – Dormant Projects, 2021 (Contd..2)

List of Figures

List of Figures

Number of Products under Development for Insulin Resistance, 2021

Number of Products under Development by Companies, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports